CERS
Cerus Corporation
NASDAQ · Healthcare · Medical - Devices · US
$2.59
+0.78%Year over year
Reported trailing growth
- Revenue
- +15.1%
- EBITDA
- +133.7%
- EBIT
- +90.7%
- EPS
- +63.9%
- Free cash flow
- —
- Operating cash flow
- -57.7%
Forward estimates
Based on analyst estimates
- Revenue
- +19.0%
- EBITDA
- +37.4%
- EPS
- +24.0%
Three-year CAGR
- Revenue
- +8.4%
- EBITDA
- +45.0%
- EBIT
- +39.0%
- Net income
- +25.3%
- EPS
- +25.5%
- Free cash flow
- +0.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026